Home
Search:
1146 feeds
357 categories
10654 articles (<24 hours)
9 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


Valid HTML 4.01 Transitional

RSS FeedsINVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
(WorldNews Health)

 
 

14 november 2017 15:58:43

 
INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
(WorldNews Health)
 




INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events Late-breaking study shows improved renal and heart failure outcomes also seen with INVOKANAin both of these patient groups RARITAN, N.J.and ANAHEIM, Calif.,November 14, 2017 - Janssen Research & Development, LLC (Janssen) today announced a new analysis from the CANVAS Program, which showed INVOKANA (canagliflozin) demonstrated a reduced risk of cardiovascular (CV) outcomes in patients with and without a history of CV disease. INVOKANA also achieved similar and proportional risk reductions for hospitalization due to heart failure (HHF) and renal...
 
11 viewsCategory: Science > Medicine
 
No changes planned for Louisiana Medicaid deal extensions
(WorldNews Health)
Genworth 2017 Annual Cost of Care Survey: Home Health Care Costs Remained Flat in Colorado; Overall Costs Up
(WorldNews Health)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2018 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn